-

Agilent Announced as Instrument Business Outlook 2022 Company of the Year

Industry newsletter cites financial performance, innovation and operational achievements

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it has been selected as Instrument Business Outlook (IBO) 2022 Company of the Year. IBO highlighted Agilent's increased growth in revenues, operating profit, and net income, noting that the gains resulted from a sustained effort to position the company for future growth.

Innovations noted included the HydroInert source, which allows for using of hydrogen instead of helium as the carrier gas in GC/MS. Also, the introductions of new versions of the AssayMAP Bravo Protein Sample Prep Workbench and the Seahorse XF Pro Analyzer. Innovation also took the form of acquisitions bringing in new technology and expertise for future growth, including expanding artificial intelligence (AI) capabilities with the acquisition of Virtual Control, a software that works with LC/MS and GC/MS to automate the analysis of instrument data. Agilent also acquired Polymer Standards Service (PSS) and ECD technology company e-MSion, adding to solutions for analyzing molecular structures and continuing to build capabilities to serve the biopharma industry.

Operationally, Agilent’s significant commitment to ESG goals was noted, including a commitment to net-zero greenhouse gas emissions by 2050, partnership activities with MyGreenLab, expansion of the Agilent’s Certified Pre-owned Instruments business, and a new agreement with How2Recyle for standardized recycling labeling.

Tanya Samazan, managing editor at IBO noted: “Agilent’s achievements were about annual results as well as years of transforming the company. Agilent thrived in 2022, showing a strong sales performance, stepped up sustainability initiatives, manufacturing expansion, and new product and M&A investments to feed future growth.”

“We are pleased that IBO has once again bestowed Agilent the tribute of being their Company of the Year, having received the same accolade in 2017,” said Mike McMullen, Agilent president and CEO. “It’s rewarding to be recognized for our team’s ongoing commitment to developing and delivering high-quality, reliable, and innovative products and solutions to our customers globally.”

IBO is a highly respected industry newsletter that tracks trends in the laboratory products markets, monitoring hundreds of life science and analytical instrument companies on a daily basis. IBO is a publication of SDi, a division of BioInformatics LLC, which offers custom market research and consulting, and strategic advisory services.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in the life sciences, diagnostics, and applied chemical markets, delivering insight and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.85 billion in fiscal 2022 and employs 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Naomi Goumillout
Agilent Technologies
+1.781.266.2819
naomi.goumillout@agilent.com

More News From Agilent Technologies Inc.

Agilent Reports First-Quarter Fiscal Year 2026 Financial Results

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025. First-quarter GAAP net income was $305 million, or $1.07 per share. This compares with $318 million, or $1.11 per share, in the first quarter of 2025. Non-GAAP(2) net income was $386 million, or $1.36 per share, during the quarter, compared wi...

Agilent to Participate in TD Cowen’s 46th Annual Health Care Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Chief Financial Officer Adam Elinoff and Head of Investor Relations Tejas Savant will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference. The event is scheduled for 11:10 to 11:40 a.m. EST on Tuesday, March 3, 2026, in Boston, Massachusetts. A live audio webcast and replay of the presentation will be available through Agilent’s Investor Relations website. About Agilent Tec...

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...
Back to Newsroom